Exo-Fect™ Exosome Transfection Kit

Turn your exosomes into delivery vehicles with Exo-Fect—enables insertion of RNAs, DNAs (including plasmids), and small molecules into isolated exosomes.
  • Easy-to-use with a fast and straightforward loading protocol
  • Introduces a wide range of biomolecules directly into isolated exosomes:
    • RNAs, including siRNAs, miRNAs, and mRNAs
    • DNAs, including plasmids
    • Metabolites and other small molecules

Products

Catalog Number Description Size Price Quantity Add to Cart
EXFT10A-1 Exo-Fect Exosome Transfection Kit 10 Reactions $247
- +
EXFT20A-1 Exo-Fect Exosome Transfection Kit 20 Reactions $445
- +

Overview

Overview

Putting exosomes to work: Load your cargo directly into isolated exosomes With Exo-Fect, you can turn isolated exosomes into cargo delivery vehicles that introduce RNAs, DNAs (including plasmids), and even small molecules into recipient cells. Simply combine isolated exosomes with Exo-Fect and your desired cargo, and in less than an hour your loaded exosomes will be ready to add to recipient cells. Exo-Fect turns your exosomes into cargo delivery vehicles
  • Easy-to-use with a fast and straightforward loading protocol
  • Introduces a wide range of biomolecules directly into isolated exosomes:
    • RNAs, including siRNAs, miRNAs, and mRNAs
    • DNAs, including plasmids
    • Metabolites and other small molecules
  • Enables non-viral transduction and stable cell line creation
  • Provides an alternative gene delivery method for hard-to-transfect cells
All Exo-Fect Kits come with a Texas Red-labeled positive control, non-targeting siRNA to confirm exosome transfections. Pair with our EV-Entry Reagent and maximize cargo uptake by recipient cells.

References

How It Works

How It Works

Quickly and easily load cargo into isolated exosomes

Simply combine the isolated exosomes with Exo-Fect Reagent and cargo, perform two incubations for a total of 40 minutes, and then pellet your exosomes. The Kit comes with all of the reagents you need to load cargo into exosomes and concentrate them for delivery to target cells. The protocol takes less than an hour and is highly efficient at loading cargo into exosomes for transport and delivery.

Exo-Fect is also compatible with the EV-Entry Reagent, which maximizes cargo uptake by recipient cells.

Supporting Data

Supporting Data

See how Exo-Fect can be used to create cargo-delivering exosomes

Exo-Fect efficiently loads small RNAs into exosomes for delivery to recipient cells
 
Exo-Fect efficiently loads siRNA into exosomes.

Figure 1. Exo-Fect efficiently loads siRNA into exosomes. Fluorescence imaging shows exosomes that were loaded with either a Texas Red end-labeled siRNA (left panels), or unlabeled siRNA (right panels) using Exo-Fect, and then immobilized onto Exo-Flow™ CD63 magnetic beads.

Exo-Fect transfected exosomes deliver siRNA cargo to recipient cells

Figure 2. Exo-Fect transfected exosomes deliver siRNA cargo to recipient cells. The siRNA-loaded exosomes from Figure 1 were eluted from the Exo-Flow CD63 magnetic beads and then added to HEK293 cells. Fluorescence of the recipient cells indicates that the Texas Red-labeled siRNA cargo was successfully delivered.

Exo-Fect efficiently loads mRNAs and DNA plasmids into exosomes for delivery to recipient cells
 Exo-Fect loaded exosomes deliver mRNA and plasmid DNA into recipient cells

Figure 3. Exo-Fect loaded exosomes deliver mRNA and plasmid DNA into recipient cells. ExoFect Kits also work with larger nucleic acids, like mRNAs and plasmids. (Left panels) We used Exo-Fect to transfect 1 µg of an mRNA encoding RFP into exosomes. These exosomes were then added to HEK293 cells and imaged for RFP protein production after 24 hours. (Right panels) We used Exo-Fect to transfect 5 µg of plasmid DNA encoding a GFP gene into exosomes, and then added the plasmid-loaded exosomes to HEK293 cells. The cells were imaged for GFP protein presence after 48 hours. The appearance of RFP signal (mRNA cargo) and GFP signal (plasmid cargo) in recipient cells indicates successful cargo delivery.

Exo-Fect efficiently loads small molecules into exosomes for delivery to recipient cellsExo-Fect transfects the small molecule cumate into exosomesExo-Fect transfects the small molecule cumate into exosomes

Figure 4. Exo-Fect can even be used to transfect small molecules into exosomes. We loaded cumate into exosomes using Exo-Fect, and then added loaded exosomes to cells containing a cumate-inducible GFP reporter construct. Only cumate-containing exosomes were able to induce GFP expression in recipient cells, indicating successful delivery of cumate.

FAQs

Exo-Fect is a novel nucleic acid transfer agent that facilitates the transfection of nucleic acids directly into isolated exosomes. These transfected exosomes can then deliver the nucleic acids into target cells.
Exo-Fect can transfect si/miRNA, mRNA, and even plasmid DNA into isolated exosomes.
The Exo-Fect transfection protocol takes less than an hour to complete.
The kit comes in two sizes, each containing Exo-Fect Reagent, Positive Control siRNA (TX-Red), and ExoQuickTC. The specific quantities differ depending on whether you get the 10 reaction or 20 reaction kit.
Although only in vitro data has been established and no internal data is available for in vivo experiments, it's possible that the transfected exosomes may be used for in vivo studies.
The transfected exosomes can be added to any target cells, including those used in cell culture, depending on your experimental requirements.
Exo-Fect has been successfully used to transfect exosomes with small RNAs, longer mRNAs, and plasmid DNA. Cells treated with these transfected exosomes have demonstrated successful uptake and expression of these nucleic acids.
Transfected exosomes can be added to the cells in a culture plate grown in exosome-depleted FBS media. The quantity can be adjusted depending on your experimental requirements.
No, according to U.S, Australian, and EU regulations, Exo-Fect does not require an MSDS because it does not contain components above the thresholds for hazardous or carcinogenic substances.

Resources

Citations

  • Bader, J, et al. (2024) Loading of extracellular vesicles with nucleic acids via hybridization with sponge-like lipid nanoparticles. bioRxiv. 2024;. Link: bioRxiv
  • Heo, J & Ryu, J. (2024) Exosomal noncoding RNA: a potential therapy for retinal vascular diseases. Molecular Therapy - Nucleic Acids. 2024;:102128. Link: Molecular Therapy - Nucleic Acids
  • Zhang, L, et al. (2024) Engineering M2 type macrophage-derived exosomes for autoimmune hepatitis immunotherapy via loading siRIPK3. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024; 171:116161. PM ID: 38244330
  • Xu, K, et al. (2024) Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions. Nature communications. 2024; 15(1):1685. PM ID: 38402239
  • Guan, T, et al. (2024) Oxidized SOD1 accelerates cellular senescence in neural stem cells. Stem cell research & therapy. 2024; 15(1):55. PM ID: 38414053
  • Mao, Y, et al. (2024) Hypoxia induced exosomal Circ-ZNF609 promotes pre-metastatic niche formation and cancer progression via miR-150-5p/VEGFA and HuR/ZO-1 axes in esophageal squamous cell carcinoma. Cell death discovery. 2024; 10(1):133. PM ID: 38472174
  • Zhang, Y, et al. (2024) Islet-resident macrophage-derived miR-155 promotes β cell decompensation via targeting PDX1. iScience. 2024; 27(4):109540. Link: iScience
  • Chen, JG, et al. (2024) Engineered hsa-miR-455-3p-Abundant Extracellular Vesicles Derived from 3D-Cultured Adipose Mesenchymal Stem Cells for Tissue-Engineering Hyaline Cartilage Regeneration. Advanced healthcare materials. 2024;:e2304194. PM ID: 38508211
  • Jiang, P, et al. (2024) RVG29 Peptide-Modified Exosomes Loaded with Mir-133b Mediate the RhoA-ROCK Pathway to Improve Motor and Neurological Symptoms in Parkinson’s Disease. ACS biomaterials science & engineering. 2024;. PM ID: 38578110
  • Sun, H, et al. (2024) C166 EVs potentiate miR cardiac reprogramming via miR-148a-3p. Journal of molecular and cellular cardiology. 2024; 190:48-61. PM ID: 38582260
  • Zheng, Z, et al. (2023) Acinous cell AR42J-derived exosome miR125b-5p promotes acute pancreatitis exacerbation by inhibiting M2 macrophage polarization via PI3K/AKT signaling pathway. World Journal of Gastrointestinal Surgery. 2023; 15(4):600-620. Link: World Journal of Gastrointestinal Surgery
  • Lang, HL, et al. (2023) Small extracellular vesicles secreted by induced pluripotent stem cell-derived mesenchymal stem cells improve postoperative cognitive dysfunction in mice with diabetes. Neural regeneration research. 2023; 18(3):609-617. PM ID: 36018185
  • Lin, W, et al. (2023) Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nature communications. 2023; 14(1):265. PM ID: 36650153
  • Zhao, W, et al. (2023) Accelerating corneal wound healing using exosome-mediated targeting of NF-κB c-Rel. Inflammation and regeneration. 2023; 43(1):6. PM ID: 36703231
  • Lu, Y, et al. (2023) Exosome-Based Carrier for RNA Delivery: Progress and Challenges. Pharmaceutics. 2023; 15(2). PM ID: 36839920
  • Ellipilli, S, et al. (2023) Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression. Nanomedicine : nanotechnology, biology, and medicine. 2023; 50:102667. PM ID: 36948369
  • Hao, L, et al. (2023) Bone targeting miR-26a loaded exosome-mimetics for bone regeneration therapy by activating Wnt signaling pathway. Chemical Engineering Journal. 2023; 471:144594. Link: Chemical Engineering Journal
  • Xie, W, et al. (2023) Inhibition of osteosarcoma by European Mistletoe derived val-miR218. Extracellular Vesicles and Circulating Nucleic Acids. 2023; 4(2):306-322. Link: Extracellular Vesicles and Circulating Nucleic Acids
  • Chen, Y, et al. (2023) Sertoli cell-derived extracellular vesicles traverse the blood-testis barrier and deliver miR-24-3p inhibitor into germ cells improving sperm mobility. Journal of controlled release : official journal of the Controlled Release Society. 2023; 362:58-69. PM ID: 37595666
  • Xiao, Y, et al. (2023) Thermos-responsive hydrogel system encapsulated engineered exosomes attenuate inflammation and oxidative damage in acute spinal cord injury. Frontiers in bioengineering and biotechnology. 2023; 11:1216878. PM ID: 37614633

Products

Catalog Number Description Size Price Quantity Add to Cart
EXFT10A-1 Exo-Fect Exosome Transfection Kit 10 Reactions $247
- +
EXFT20A-1 Exo-Fect Exosome Transfection Kit 20 Reactions $445
- +

Overview

Overview

Putting exosomes to work: Load your cargo directly into isolated exosomes With Exo-Fect, you can turn isolated exosomes into cargo delivery vehicles that introduce RNAs, DNAs (including plasmids), and even small molecules into recipient cells. Simply combine isolated exosomes with Exo-Fect and your desired cargo, and in less than an hour your loaded exosomes will be ready to add to recipient cells. Exo-Fect turns your exosomes into cargo delivery vehicles
  • Easy-to-use with a fast and straightforward loading protocol
  • Introduces a wide range of biomolecules directly into isolated exosomes:
    • RNAs, including siRNAs, miRNAs, and mRNAs
    • DNAs, including plasmids
    • Metabolites and other small molecules
  • Enables non-viral transduction and stable cell line creation
  • Provides an alternative gene delivery method for hard-to-transfect cells
All Exo-Fect Kits come with a Texas Red-labeled positive control, non-targeting siRNA to confirm exosome transfections. Pair with our EV-Entry Reagent and maximize cargo uptake by recipient cells.

References

How It Works

How It Works

Quickly and easily load cargo into isolated exosomes

Simply combine the isolated exosomes with Exo-Fect Reagent and cargo, perform two incubations for a total of 40 minutes, and then pellet your exosomes. The Kit comes with all of the reagents you need to load cargo into exosomes and concentrate them for delivery to target cells. The protocol takes less than an hour and is highly efficient at loading cargo into exosomes for transport and delivery.

Exo-Fect is also compatible with the EV-Entry Reagent, which maximizes cargo uptake by recipient cells.

Supporting Data

Supporting Data

See how Exo-Fect can be used to create cargo-delivering exosomes

Exo-Fect efficiently loads small RNAs into exosomes for delivery to recipient cells
 
Exo-Fect efficiently loads siRNA into exosomes.

Figure 1. Exo-Fect efficiently loads siRNA into exosomes. Fluorescence imaging shows exosomes that were loaded with either a Texas Red end-labeled siRNA (left panels), or unlabeled siRNA (right panels) using Exo-Fect, and then immobilized onto Exo-Flow™ CD63 magnetic beads.

Exo-Fect transfected exosomes deliver siRNA cargo to recipient cells

Figure 2. Exo-Fect transfected exosomes deliver siRNA cargo to recipient cells. The siRNA-loaded exosomes from Figure 1 were eluted from the Exo-Flow CD63 magnetic beads and then added to HEK293 cells. Fluorescence of the recipient cells indicates that the Texas Red-labeled siRNA cargo was successfully delivered.

Exo-Fect efficiently loads mRNAs and DNA plasmids into exosomes for delivery to recipient cells
 Exo-Fect loaded exosomes deliver mRNA and plasmid DNA into recipient cells

Figure 3. Exo-Fect loaded exosomes deliver mRNA and plasmid DNA into recipient cells. ExoFect Kits also work with larger nucleic acids, like mRNAs and plasmids. (Left panels) We used Exo-Fect to transfect 1 µg of an mRNA encoding RFP into exosomes. These exosomes were then added to HEK293 cells and imaged for RFP protein production after 24 hours. (Right panels) We used Exo-Fect to transfect 5 µg of plasmid DNA encoding a GFP gene into exosomes, and then added the plasmid-loaded exosomes to HEK293 cells. The cells were imaged for GFP protein presence after 48 hours. The appearance of RFP signal (mRNA cargo) and GFP signal (plasmid cargo) in recipient cells indicates successful cargo delivery.

Exo-Fect efficiently loads small molecules into exosomes for delivery to recipient cellsExo-Fect transfects the small molecule cumate into exosomesExo-Fect transfects the small molecule cumate into exosomes

Figure 4. Exo-Fect can even be used to transfect small molecules into exosomes. We loaded cumate into exosomes using Exo-Fect, and then added loaded exosomes to cells containing a cumate-inducible GFP reporter construct. Only cumate-containing exosomes were able to induce GFP expression in recipient cells, indicating successful delivery of cumate.

FAQs

Exo-Fect is a novel nucleic acid transfer agent that facilitates the transfection of nucleic acids directly into isolated exosomes. These transfected exosomes can then deliver the nucleic acids into target cells.
Exo-Fect can transfect si/miRNA, mRNA, and even plasmid DNA into isolated exosomes.
The Exo-Fect transfection protocol takes less than an hour to complete.
The kit comes in two sizes, each containing Exo-Fect Reagent, Positive Control siRNA (TX-Red), and ExoQuickTC. The specific quantities differ depending on whether you get the 10 reaction or 20 reaction kit.
Although only in vitro data has been established and no internal data is available for in vivo experiments, it's possible that the transfected exosomes may be used for in vivo studies.
The transfected exosomes can be added to any target cells, including those used in cell culture, depending on your experimental requirements.
Exo-Fect has been successfully used to transfect exosomes with small RNAs, longer mRNAs, and plasmid DNA. Cells treated with these transfected exosomes have demonstrated successful uptake and expression of these nucleic acids.
Transfected exosomes can be added to the cells in a culture plate grown in exosome-depleted FBS media. The quantity can be adjusted depending on your experimental requirements.
No, according to U.S, Australian, and EU regulations, Exo-Fect does not require an MSDS because it does not contain components above the thresholds for hazardous or carcinogenic substances.

Citations

  • Bader, J, et al. (2024) Loading of extracellular vesicles with nucleic acids via hybridization with sponge-like lipid nanoparticles. bioRxiv. 2024;. Link: bioRxiv
  • Heo, J & Ryu, J. (2024) Exosomal noncoding RNA: a potential therapy for retinal vascular diseases. Molecular Therapy - Nucleic Acids. 2024;:102128. Link: Molecular Therapy - Nucleic Acids
  • Zhang, L, et al. (2024) Engineering M2 type macrophage-derived exosomes for autoimmune hepatitis immunotherapy via loading siRIPK3. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024; 171:116161. PM ID: 38244330
  • Xu, K, et al. (2024) Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions. Nature communications. 2024; 15(1):1685. PM ID: 38402239
  • Guan, T, et al. (2024) Oxidized SOD1 accelerates cellular senescence in neural stem cells. Stem cell research & therapy. 2024; 15(1):55. PM ID: 38414053
  • Mao, Y, et al. (2024) Hypoxia induced exosomal Circ-ZNF609 promotes pre-metastatic niche formation and cancer progression via miR-150-5p/VEGFA and HuR/ZO-1 axes in esophageal squamous cell carcinoma. Cell death discovery. 2024; 10(1):133. PM ID: 38472174
  • Zhang, Y, et al. (2024) Islet-resident macrophage-derived miR-155 promotes β cell decompensation via targeting PDX1. iScience. 2024; 27(4):109540. Link: iScience
  • Chen, JG, et al. (2024) Engineered hsa-miR-455-3p-Abundant Extracellular Vesicles Derived from 3D-Cultured Adipose Mesenchymal Stem Cells for Tissue-Engineering Hyaline Cartilage Regeneration. Advanced healthcare materials. 2024;:e2304194. PM ID: 38508211
  • Jiang, P, et al. (2024) RVG29 Peptide-Modified Exosomes Loaded with Mir-133b Mediate the RhoA-ROCK Pathway to Improve Motor and Neurological Symptoms in Parkinson’s Disease. ACS biomaterials science & engineering. 2024;. PM ID: 38578110
  • Sun, H, et al. (2024) C166 EVs potentiate miR cardiac reprogramming via miR-148a-3p. Journal of molecular and cellular cardiology. 2024; 190:48-61. PM ID: 38582260
  • Zheng, Z, et al. (2023) Acinous cell AR42J-derived exosome miR125b-5p promotes acute pancreatitis exacerbation by inhibiting M2 macrophage polarization via PI3K/AKT signaling pathway. World Journal of Gastrointestinal Surgery. 2023; 15(4):600-620. Link: World Journal of Gastrointestinal Surgery
  • Lang, HL, et al. (2023) Small extracellular vesicles secreted by induced pluripotent stem cell-derived mesenchymal stem cells improve postoperative cognitive dysfunction in mice with diabetes. Neural regeneration research. 2023; 18(3):609-617. PM ID: 36018185
  • Lin, W, et al. (2023) Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nature communications. 2023; 14(1):265. PM ID: 36650153
  • Zhao, W, et al. (2023) Accelerating corneal wound healing using exosome-mediated targeting of NF-κB c-Rel. Inflammation and regeneration. 2023; 43(1):6. PM ID: 36703231
  • Lu, Y, et al. (2023) Exosome-Based Carrier for RNA Delivery: Progress and Challenges. Pharmaceutics. 2023; 15(2). PM ID: 36839920
  • Ellipilli, S, et al. (2023) Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression. Nanomedicine : nanotechnology, biology, and medicine. 2023; 50:102667. PM ID: 36948369
  • Hao, L, et al. (2023) Bone targeting miR-26a loaded exosome-mimetics for bone regeneration therapy by activating Wnt signaling pathway. Chemical Engineering Journal. 2023; 471:144594. Link: Chemical Engineering Journal
  • Xie, W, et al. (2023) Inhibition of osteosarcoma by European Mistletoe derived val-miR218. Extracellular Vesicles and Circulating Nucleic Acids. 2023; 4(2):306-322. Link: Extracellular Vesicles and Circulating Nucleic Acids
  • Chen, Y, et al. (2023) Sertoli cell-derived extracellular vesicles traverse the blood-testis barrier and deliver miR-24-3p inhibitor into germ cells improving sperm mobility. Journal of controlled release : official journal of the Controlled Release Society. 2023; 362:58-69. PM ID: 37595666
  • Xiao, Y, et al. (2023) Thermos-responsive hydrogel system encapsulated engineered exosomes attenuate inflammation and oxidative damage in acute spinal cord injury. Frontiers in bioengineering and biotechnology. 2023; 11:1216878. PM ID: 37614633